Branch of glucose metabolism that diverts F6P → UDP-N-acetylglucosamine (UDP-GlcNAc), the substrate for: (1) O-GlcNAc protein modification (analogous to phosphorylation, dynamic regulation of metabolic + transcription factors); (2) N-linked glycoprotein synthesis (ER); (3) glycosaminoglycan biosynthesis (hyaluronan, chondroitin, heparan sulfate). The committed step is GFAT (glutamine fructose-6-P aminotransferase). Flux is glucose-sensitive — diabetic hyperglycemia drives increased UDP-GlcNAc + increased O-GlcNAcylation, a proposed mechanism in diabetic vascular complications. GLUCOSAMINE supplementation enters at the F6P-amination step; clinical evidence for joint-disease effects is mixed.
Organ Systems
musculoskeletal
integumentary
endocrine
Pathway Steps
fructose-6-phosphate → glucosamine-6-phosphate — via GFAT (glutamine-fructose-6-P amidotransferase) — RATE-LIMITING; glutamine N-donor. GFAT diverts fructose-6-phosphate plus glutamine into the hexosamine biosynthesis pathway — the rate-limiting step and a nutrient sensor whose flux scales with glucose, glutamine, acetyl-CoA, and UTP availability.
glucosamine-6-phosphate → udp-glcnac — via multi-step (GNA + AGM + UAP). The pathway ends in UDP-GlcNAc, the donor for N-/O-glycosylation and for O-GlcNAcylation — a nutrient-responsive signaling modification linked to insulin resistance and to glucosamine supplementation’s proposed effects.